AnaptysBio
ANAB
122 hedge funds and large institutions have $670M invested in AnaptysBio in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 45 reducing their positions, and 19 closing their positions.
52% more capital invested
Capital invested by funds: $441M → $670M (+$229M)
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
5% more funds holding
Funds holding: 116 → 122 (+6)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
5.14% less ownership
Funds ownership: 115.1% → 109.96% (-5.1%)
33% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 45
84% less call options, than puts
Call options by funds: $574K | Put options by funds: $3.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$10.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$5.1M |
| 3 |
D.E. Shaw & Co
New York
|
+$4.42M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.35M |
| 5 |
Goldman Sachs
New York
|
+$4.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.49M |
| 2 |
Morgan Stanley
New York
|
-$8.86M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$7.24M |
| 4 |
PA
Perceptive Advisors
New York
|
-$7.07M |
| 5 |
KAM
Krensavage Asset Management
New York
|
-$4.74M |
ANAB Hedge Fund Activity: Q2 2020 in Review
122 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2020, worth a combined $670M — up 52% from $441M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ANAB positions and 19 closed out — a net gain of 6 holders — while 30 added to existing stakes and 45 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $10.4M. The largest seller was State Street, cutting an estimated $9.49M.
- 122 institutional investors held AnaptysBio (ANAB) as of Q2 2020, up from 116 in Q1 2020.
- Funds reported $670M of AnaptysBio stock for Q2 2020, up 52% quarter-over-quarter.
- 25 funds opened new AnaptysBio positions in Q2 2020 and 19 closed out, a net change of +6 holders.
- The largest AnaptysBio buyer in Q2 2020 was Citadel Advisors, an estimated $10.4M added.
- The largest AnaptysBio seller in Q2 2020 was State Street, an estimated $9.49M sold.
Based on aggregated 13F filings for Q2 2020.